Clinical trial
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy…
NCT00148512 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00148512 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations |
| Official title | A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | 1. Tesofensine (NS 2330) |
| Enrollment | 254 |
| Start date | Mar 1, 2003 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Oct 29, 2013 |
| Countries | Austria, France, Germany, Netherlands, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: